Loading
institutionsInstitution
Cancer Prevention and Research Institute of Texas
The Texas state agency created by voters in 2007 that is the second-largest public funder of cancer research in the US after the NCI.
Also called: CPRIT
Overview
CPRIT was created by a 2007 Texas constitutional amendment authorising $3 billion in bonds for cancer research and prevention, and voters approved a further $3 billion in 2019. It awards academic research grants, recruits scientists to Texas institutions through Scholar awards, funds prevention and screening services in underserved communities and invests in Texas-based cancer companies through its product development programme. CPRIT funding has helped build programmes at MD Anderson, UT Southwestern, Baylor and other Texas centres and has recruited hundreds of investigators to the state. Its oversight committee and peer-review panels are drawn largely from outside Texas.
Location
Austin, TX, US
Type
government
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#370 · 16 points (0 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Cancer Prevention and Research Institute of Texas, including child institutions. 5 works · 132 citations · 80% open access · 0% clinical trials · 0% reviews.
Oncology works per year
12022
22023
12024
02025
12026
Most works
- Rajat Bannerji1 works
- Esther Bachar-Lustig1 works
- Katayoun Rezvani1 works
- Ryan C. Ramphul1 works
- Yixiao Chen1 works
- Robert Allen Smith1 works
- Giuseppe Gritti1 works
- Sam Yuen1 works
- Wei-Hsin Liu1 works
- Avichai Shimoni1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Cancer-Associated Hypercalcemia 10.1056/nejmcp2113128 | New England Journal of Medicine | 2022 | 111 |
| Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma 10.1002/ajh.27341 · open access | American Journal of Hematology | 2024 | 12 |
| The modeling of multicancer early detection (MCED) tests’ residual risk and the challenges of MCED evaluation and implementation 10.1002/cncr.34745 · open access | Cancer | 2023 | 6 |
| Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy 10.1016/j.jtct.2023.10.016 · open access | Transplantation and Cellular Therapy | 2023 | 3 |
| Long-Term Poverty, Rurality, and Geographic Disparities in Colorectal Cancer: A Spatial Analysis in Texas | Research Square | 2026 | 0 |
- Academic research grants
- Scholar recruitment awards
- Prevention and screening services
- Product development research (company investments)
Similar pages
- IdeaA public-benefit phase 1 factory that takes academic discoveries into first-in-human trials
Shares The valley of death between lab and product, Funding follows fashion, not burden, National Cancer Institute (NIH).
- IdeaA diversified royalty pool that finances academic phase 1 trials across fifty assets
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product.
- InstitutionThe V Foundation for Cancer Research
Shares The valley of death between lab and product, MD Anderson Cancer Center, National Cancer Institute (NIH).
- PersonMonroe Dunaway Anderson
Shares MD Anderson Cancer Center, Funding follows fashion, not burden.
- IdeaA fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product.
- PersonDavid H. Koch
Shares The valley of death between lab and product, MD Anderson Cancer Center, Funding follows fashion, not burden.
- PersonWalter Winchell
Shares Not enough oncologists, nurses, pathologists, physicists, Funding follows fashion, not burden.
- IdeaPublish per-patient trial cost benchmarks and target halving them
Shares Funding follows fashion, not burden, National Cancer Institute (NIH).